More Referrals Won't Fix Enrollment
Why the Clinical Trial Industry May Be Optimizing the Wrong Part of the Enrollment Funnel
The industry is excellent at generating interest. But sites need verified patients, not just more referrals.
EXECUTIVE SUMMARY
The clinical trial industry has become exceptionally good at generating patient referrals. Sponsors invest millions of dollars each year in digital advertising, recruitment vendors, advocacy partnerships, and outreach programs designed to bring more patients into clinical trials.
Yet despite these investments, many studies continue to face the same challenges:
High screen-failure rates
Missed enrollment timelinesThe industry's response has largely been consistent: generate more referrals.
But what if referral volume is not the primary problem?
What if sites do not need more referrals?
What if they need more verified patients?
This paper explores what we believe is one of the most overlooked challenges in clinical research today:
THE PATIENT READINESS GAP.
THE REFERRAL MYTH
For years, the industry has operated under a simple assumption:
"MORE REFERRALS LEAD TO MORE ENROLLMENTS."
Yet many sites report a different reality. Patients arrive interested in participating but lack the clinical documentation necessary to determine whether they actually qualify.
THE BREAKDOWN OF A FALSE POSITIVE REFERRAL
A patient who appears eligible but ultimately fails due to information that could have been known earlier.
The clinical trial industry has spent decades optimizing patient acquisition. The next major opportunity may be optimizing patient readiness.
THE PATIENT READINESS GAP
Why So Many Good Intentions Don't Lead to Enrollments
Between the initial referral and the final enrollment decision lies a gap that costs time, money, and trust. Sites are asked to solve problems they were never resourced to solve.
IDENTIFICATION
Finding the right patients within the site's own EMR
Many sites already have thousands of potentially eligible patients in their EMR systems, but lack the time, resources, or expertise to find them.
VERIFICATION
Determining if patients actually qualify
Patient self-reporting is valuable, but often insufficient for protocol-level decision making. Objective clinical data is essential.
ACTIVATION
Moving verified patients quickly toward enrollment
Even when patients appear eligible, delays in scheduling and evaluation can lead to loss of engagement and extended timelines.
THE HIDDEN COST OF A FALSE POSITIVE REFERRAL
A patient who appears eligible but ultimately fails due to information that could have been known earlier.
A single false positive consumes 4-8 hours of site resources on average. Multiply that by hundreds of referrals, and the impact is substantial.
Wasted Time
Coordinator, nurse, and investigator time diverted from patients who may actually qualify.
Wasted Resources
Operational costs increase without a corresponding increase in enrollments.
Delayed Enrollments
Time spent on unqualified patients delays focus on those who could enroll.
Eroded Trust
Sites lose confidence in referral quality and become more cautious and selective.
THE IMPACT ON SITE TRUST
When large numbers of referrals fail due to missing or incomplete information, confidence in the process erodes.
Skepticism toward referral sources increases.
Site morale and engagement decline.
Sites become more reluctant to prioritize future studies.
Every false positive referral consumes more than resources. It consumes trust.
EVERY FALSE-POSITIVE REFERRAL CONSUMES MORE THAN COORDINATOR TIME. IT ALSO ERODES SITE CONFIDENCE IN THE ENROLLMENT PROCESS.
THE FUTURE OF ENROLLMENT IS PATIENT READINESS
The next breakthrough in clinical trials will not come from generating more referrals. It will come from delivering better prepared patients.
The goal is not more referrals. The goal is fewer surprises.
When patients arrive with the right information, sites can make faster decisions, enroll more qualified patients, and focus on what matters most—advancing science.
OUTCOME
A NEW WAY TO THINK ABOUT SITE SELECTION
Study → Site → Patient
Study is designed
Sites are selected
Patients are then sought
Enrollment outcomes varyWhat if we flipped the script?
What if sites could be identified because they already have patients who match the protocol?
Patient → Site → Study
Patients are identified in real-world data
Sites with matching patients are surfaced
Studies are matched to the right sites
Better matches. Better enrollment.WHY THIS MATTERS
Shorter start-up times
Less time searching. More time enrolling.
Lower overall costs
Fewer inefficiencies. Better resource use.
Higher enrollment rates
Better matches lead to better outcomes.
Reduced site burden
Sites spend less time chasing and more time enrolling.
THE NEXT DECADE OF ENROLLMENTFIVE PREDICTIONS
THE IMPACT ON SPONSORS, CROS, AND SITES
For Sponsors
For CROs
For Sites
THE FUTURE BELONGS TO THOSE WHO PREPARE FOR IT TODAY.
Moving from referral volume to patient readiness is not just an operational improvement. It is the foundation for a more efficient, effective, and sustainable clinical trial ecosystem.
THE TAKEAWAY
Get In Touch
Get In Touch
